FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155171645> ?p ?o ?g. }

• W2155171645 endingPage "53" @default.
• W2155171645 startingPage "41" @default.
• W2155171645 abstract "Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antiretroviral therapy (ART) reduces morbidity in children infected with the human immunodeficiency virus (HIV). We investigated whether children and adolescents receiving long-term ART in sub-Saharan Africa could discontinue co-trimoxazole.We conducted a randomized, noninferiority trial of stopping versus continuing daily open-label co-trimoxazole in children and adolescents in Uganda and Zimbabwe. Eligible participants were older than 3 years of age, had been receiving ART for more than 96 weeks, were using insecticide-treated bed nets (in malaria-endemic areas), and had not had Pneumocystis jirovecii pneumonia. Coprimary end points were hospitalization or death and adverse events of grade 3 or 4.A total of 758 participants were randomly assigned to stop or continue co-trimoxazole (382 and 376 participants, respectively), after receiving ART for a median of 2.1 years (interquartile range, 1.8 to 2.3). The median age was 7.9 years (interquartile range, 4.6 to 11.1), and the median CD4 T-cell percentage was 33% (interquartile range, 26 to 39). Participants who stopped co-trimoxazole had higher rates of hospitalization or death than those who continued (72 participants [19%] vs. 48 [13%]; hazard ratio, 1.64; 95% confidence interval [CI], 1.14 to 2.37; P = 0.007; noninferiority not shown). There was no evidence of variation across ages (P=0.93 for interaction). A total of 2 participants in the prophylaxis-stopped group (1%) died, as did 3 in the prophylaxis-continued group (1%). Most hospitalizations in the prophylaxis-stopped group were for malaria (49 events, vs. 21 in the prophylaxis-continued group) or infections other than malaria (53 vs. 25), particularly pneumonia, sepsis, and meningitis. Rates of adverse events of grade 3 or 4 were similar in the two groups (hazard ratio, 1.20; 95% CI, 0.83 to 1.72; P=0.33), but more grade 4 adverse events occurred in the prophylaxis-stopped group (hazard ratio, 2.04; 95% CI, 0.99 to 4.22; P=0.05), with anemia accounting for the largest number of events (12, vs. 2 with continued prophylaxis).Continuing co-trimoxazole prophylaxis after 96 weeks of ART was beneficial, as compared with stopping prophylaxis, with fewer hospitalizations for both malaria and infection not related to malaria. (Funded by the United Kingdom Medical Research Council and others; ARROW Current Controlled Trials number, ISRCTN24791884.)." @default.
• W2155171645 created "2016-06-24" @default.
• W2155171645 creator A5003718468 @default.
• W2155171645 creator A5004201683 @default.
• W2155171645 creator A5004747457 @default.
• W2155171645 creator A5006114405 @default.
• W2155171645 creator A5006472610 @default.
• W2155171645 creator A5030021239 @default.
• W2155171645 creator A5035610126 @default.
• W2155171645 creator A5041072379 @default.
• W2155171645 creator A5043684973 @default.
• W2155171645 creator A5043723375 @default.
• W2155171645 creator A5044933203 @default.
• W2155171645 creator A5050397750 @default.
• W2155171645 creator A5051624642 @default.
• W2155171645 creator A5074802254 @default.
• W2155171645 creator A5079332141 @default.
• W2155171645 creator A5087129711 @default.
• W2155171645 date "2014-01-02" @default.
• W2155171645 modified "2023-10-08" @default.
• W2155171645 title "A Randomized Trial of Prolonged Co-trimoxazole in HIV-Infected Children in Africa" @default.
• W2155171645 cites W1945670356 @default.
• W2155171645 cites W1971392503 @default.
• W2155171645 cites W1987018399 @default.
• W2155171645 cites W1999500342 @default.
• W2155171645 cites W2013256551 @default.
• W2155171645 cites W2018340707 @default.
• W2155171645 cites W2018659533 @default.
• W2155171645 cites W2021725162 @default.
• W2155171645 cites W2041776821 @default.
• W2155171645 cites W2042387179 @default.
• W2155171645 cites W2054870059 @default.
• W2155171645 cites W2067274027 @default.
• W2155171645 cites W2080101376 @default.
• W2155171645 cites W2085463248 @default.
• W2155171645 cites W2090740440 @default.
• W2155171645 cites W2096734250 @default.
• W2155171645 cites W2109752546 @default.
• W2155171645 cites W2110278919 @default.
• W2155171645 cites W2110596103 @default.
• W2155171645 cites W2119264739 @default.
• W2155171645 cites W2119389667 @default.
• W2155171645 cites W2125404477 @default.
• W2155171645 cites W2129257965 @default.
• W2155171645 cites W2129994024 @default.
• W2155171645 cites W2130060580 @default.
• W2155171645 cites W2130802073 @default.
• W2155171645 cites W2132136467 @default.
• W2155171645 cites W2135369095 @default.
• W2155171645 cites W2150047352 @default.
• W2155171645 cites W2159324987 @default.
• W2155171645 cites W2162881343 @default.
• W2155171645 cites W2165338002 @default.
• W2155171645 cites W2165394545 @default.
• W2155171645 cites W2167840994 @default.
• W2155171645 cites W2380034338 @default.
• W2155171645 doi "https://doi.org/10.1056/nejmoa1214901" @default.
• W2155171645 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4264559" @default.
• W2155171645 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24382064" @default.
• W2155171645 hasPublicationYear "2014" @default.
• W2155171645 type Work @default.
• W2155171645 sameAs 2155171645 @default.
• W2155171645 citedByCount "96" @default.
• W2155171645 countsByYear W21551716452014 @default.
• W2155171645 countsByYear W21551716452015 @default.
• W2155171645 countsByYear W21551716452016 @default.
• W2155171645 countsByYear W21551716452017 @default.
• W2155171645 countsByYear W21551716452018 @default.
• W2155171645 countsByYear W21551716452019 @default.
• W2155171645 countsByYear W21551716452020 @default.
• W2155171645 countsByYear W21551716452021 @default.
• W2155171645 countsByYear W21551716452022 @default.
• W2155171645 countsByYear W21551716452023 @default.
• W2155171645 crossrefType "journal-article" @default.
• W2155171645 hasAuthorship W2155171645A5003718468 @default.
• W2155171645 hasAuthorship W2155171645A5004201683 @default.
• W2155171645 hasAuthorship W2155171645A5004747457 @default.
• W2155171645 hasAuthorship W2155171645A5006114405 @default.
• W2155171645 hasAuthorship W2155171645A5006472610 @default.
• W2155171645 hasAuthorship W2155171645A5030021239 @default.
• W2155171645 hasAuthorship W2155171645A5035610126 @default.
• W2155171645 hasAuthorship W2155171645A5041072379 @default.
• W2155171645 hasAuthorship W2155171645A5043684973 @default.
• W2155171645 hasAuthorship W2155171645A5043723375 @default.
• W2155171645 hasAuthorship W2155171645A5044933203 @default.
• W2155171645 hasAuthorship W2155171645A5050397750 @default.
• W2155171645 hasAuthorship W2155171645A5051624642 @default.
• W2155171645 hasAuthorship W2155171645A5074802254 @default.
• W2155171645 hasAuthorship W2155171645A5079332141 @default.
• W2155171645 hasAuthorship W2155171645A5087129711 @default.
• W2155171645 hasBestOaLocation W21551716451 @default.
• W2155171645 hasConcept C119060515 @default.
• W2155171645 hasConcept C126322002 @default.
• W2155171645 hasConcept C168563851 @default.
• W2155171645 hasConcept C187212893 @default.
• W2155171645 hasConcept C197934379 @default.
• W2155171645 hasConcept C207103383 @default.
• W2155171645 hasConcept C2777914695 @default.

• next